The use of real-world evidence to support the FDA’s regulatory decision-making for medical devices, using patient preference information across the total product life cycle of a device, and predetermined change control plans for devices are among the agency’s top guidance development priorities for fiscal year (FY) 2026, which began Oct. 1. On Sept. 30, the FDA’s Center for D... Read More